Trial Profile

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
Indications Adenocarcinoma; Colorectal cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; First in man; Pharmacodynamics

Most Recent Events

11 Jul 2025 Status changed from recruiting to active, no longer recruiting.
30 Apr 2025 Results (n=12, At the time of data cutoff December 13, 2024) presented at the 116th Annual Meeting of the American Association for Cancer Research.
28 Feb 2024 Planned End Date changed from 8 Dec 2024 to 8 Aug 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com